<DOC>
	<DOCNO>NCT02934841</DOCNO>
	<brief_summary>The investigator hypothesize safe effective treat patient choroidal neovascularisation ( abnormal blood vessel grow retina ) secondary uveitis Conbercept . This randomized , placebo-controlled trial . 20 patient receive three injection Conbercept affect eye ( repeated injection require ) , 20 patient receive three sham injection require needle stick , make patient unaware whether received active treatment . Outcome two treatment group compare one year .</brief_summary>
	<brief_title>Conbercept Choroidal Neovascularization Secondary Uveitis</brief_title>
	<detailed_description>Primary Outcome Measures : Mean change baseline best correct visual acuity [ Time Frame : 12 month ] Secondary Outcome Measures : Mean change baseline retinal thickness [ Time Frame : 12 month ] Mean number Conbercept injection require 12 month [ Time Frame : 12 month ] Ocular systemic adverse event [ Time Frame : 12 month ] Enrollment : 40 Intervention Details : Drug : Conbercept 20 patient receive intravitreal injection conbercept 0.5 mg baseline ( visit 1 ; month 0 ) subsequent intravitreal injection month 1 ( visit 2 ) month 2 ( Visit 3 ) . Patients review every month thereafter 12 month time determine whether patient require retreatment conbercept 0.5 mg base measurement visual acuity , Optical coherence tomography ( OCT ) finding , FFA clinical appearance .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>Patient uveitis ( without sign active uveitis ) relate CNV , whatever cause , include multifocal choroiditis , punctate inner choroidopathy , ocular toxoplasmosis , serpiginous choroiditis , Birdshot chorioretinopathy VKH syndrome , etc , active primary subfoveal , retrofoveal juxtafoveal lesion affect fovea evidence angiography and/or OCT study eye Total lesion area &lt; 12 disc area . Total area CNV within lesion must &gt; 50 % total lesion . Best correct visual acuity 20/40 20/320 study eye . Willing able give inform consent . Prior treatment study eye , externalbeam radiation therapy , subfoveal focal laser photocoagulation , vitrectomy , transpupillary thermotherapy anti VEGF treatment , History submacular surgery surgical intervention study eye , glaucoma filtration surgery , corneal transplant surgery , Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within one month precede baseline , Extracapsular extraction cataract phacoemulsification within three month precede baseline , history postoperative complication within last 12 month precede baseline study eye ( uveitis , cyclitis , etc . ) , History uncontrolled glaucoma study eye ( defined intraocular pressure â‰¥ 25 mmHg despite treatment antiglaucoma medication ) , Aphakia absence posterior capsule study eye , Active intraocular inflammation ( grade trace ) study eye , Any active infection involve ocular adnexa include infectious conjunctivitis , keratitis , scleritis , endophthalmitis , Vitreous hemorrhage history rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye , Presence retinal pigment epithelial tear involve macula study eye , Subfoveal fibrosis atrophy study eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>